{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:44:28Z","timestamp":1785235468503,"version":"3.55.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Blood-based biomarkers (BBMs) are transforming the diagnostic workflow for Alzheimer\u2019s disease (AD). However, there is no consensus on the optimal phosphorylated tau (p-tau) isoform (217, 181, or 231) or analytical platform [mass spectrometry (MS) vs. immunoassay (IA)] for clinical implementation across different disease stages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To systematically compare the diagnostic accuracy and prognostic value of plasma p-tau isoforms using different technical platforms for detecting amyloid-\n                      <jats:italic>\u03b2<\/jats:italic>\n                      (A\u03b2) pathology, tau pathology, and predicting cognitive decline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection<\/jats:title>\n                    <jats:p>Studies reporting diagnostic accuracy [Area Under the Curve (AUC)] of plasma p-tau against cerebrospinal fluid (CSF) or Positron Emission Tomography (PET) standards were included. To ensure statistical independence, overlapping cohorts (e.g., BioFINDER, ADNI) were rigorously screened, selecting only the most comprehensive dataset per cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 18 high-quality studies comprising 24 independent datasets and 4,736 participants were included. For detecting A\u03b2 pathology, p-tau217 measured by MS (p217_MS) demonstrated the highest diagnostic accuracy (P-score\u202f=\u202f0.86), followed by p-tau217 ratio (p217_Ratio) (P-score\u202f=\u202f0.78) and automated immunoassays (P-score\u202f=\u202f0.67\u20130.69), all of which significantly outperformed standard p-tau181 immunoassays (P-score\u202f=\u202f0.12). Notably, the p-tau217\/A\u03b2 42 ratio on automated platforms provided a significant incremental AUC gain of 0.025 (95% CI: 0.005 to 0.045;\n                      <jats:italic>\n                        I\n                        <jats:sup>2<\/jats:sup>\n                      <\/jats:italic>\n                      \u202f=\u202f0%) compared to single-analyte assays, effectively bridging the performance gap with MS. In disease staging, while p-tau231 showed potential in detecting early amyloidosis, p-tau217_MS was superior for identifying advanced Tau-PET pathology (P-score\u202f=\u202f0.91) and predicting MCI-to-dementia conversion (P-score\u202f=\u202f0.82). Subgroup analyses confirmed consistent performance of p-tau217 across Han Chinese and Western cohorts, and demonstrated the diagnostic potential of serum-based assays as a viable matrix.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>Plasma p-tau217, particularly when measured by mass spectrometry or as a ratio on fully automated platforms, offers the highest accuracy for AD diagnosis and staging. While p-tau231 may serve as an early indicator of amyloidosis, p-tau217 is the most robust marker for tau pathology and disease progression. These findings support the integration of automated p-tau217 assays into routine clinical care to streamline patient stratification for disease-modifying therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>\n                      , identifier (CRD420261327845).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2026.1834591","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:44:53Z","timestamp":1780469093000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Diagnostic performance of plasma p-Tau217, p-Tau181, and p-Tau231 across the Alzheimer\u2019s disease continuum: a network meta-analysis"],"prefix":"10.3389","volume":"18","author":[{"given":"Xiaofen","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Affiliated Jinhua Hospital, Zhejiang University School of Medicine (Jinhua Municipal Central Hospital)","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Affiliated Jinhua Hospital, Zhejiang University School of Medicine (Jinhua Municipal Central Hospital)","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Affiliated Jinhua Hospital, Zhejiang University School of Medicine (Jinhua Municipal Central Hospital)","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuizhi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Affiliated Jinhua Hospital, Zhejiang University School of Medicine (Jinhua Municipal Central Hospital)","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwei","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Affiliated Jinhua Hospital, Zhejiang University School of Medicine (Jinhua Municipal Central Hospital)","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"","journal-title":"JAMA Neurol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1101\/2024.08.22.24312244","article-title":"The Alzheimer\u2019s association global biomarker standardization consortium (GBSC) plasma phospho-tau round Robin study","volume":"22","author":"Ashton","year":"","journal-title":"MedRxiv."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e20200861","DOI":"10.1084\/jem.20200861","article-title":"Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease","volume":"217","author":"Barth\u00e9lemy","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","article-title":"Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231","volume":"13","author":"Bayoumy","year":"2021","journal-title":"Alzheimer's Res. Ther."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/clinchem\/hvaf162","article-title":"Diagnostic value of serum p-tau217 in Alzheimer disease: equal to plasma in levels and clinical utility?","volume":"72","author":"Benedet","year":"2026","journal-title":"Clin. Chem."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/alz.12301","article-title":"Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study","volume":"17","author":"Brickman","year":"2021","journal-title":"Alzheimers Dement."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","article-title":"A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases","volume":"3","author":"Brum","year":"2023","journal-title":"Nat. Aging"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e14411","DOI":"10.1002\/alz.14411","article-title":"Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer's disease","volume":"21","author":"Devanarayan","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e12307","DOI":"10.1002\/dad2.12307","article-title":"Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum","volume":"14","author":"Dor\u00e9","year":"2022","journal-title":"Alzheimers Dement (Amst)."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e1229","DOI":"10.1212\/WNL.0000000000012513","article-title":"Associations of fully automated CSF and novel plasma biomarkers with Alzheimer disease neuropathology at autopsy","volume":"97","author":"Grothe","year":"2021","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer's disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat. Aging"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"105805","DOI":"10.1016\/j.ebiom.2025.105805","article-title":"Comparative performance of plasma pTau181\/A\u03b242, pTau217\/A\u03b242 ratios, and individual measurements in detecting brain amyloidosis","volume":"117","author":"Lehmann","year":"2025","journal-title":"EBioMedicine"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease","volume":"143","author":"Mattsson-Carlgren","year":"2020","journal-title":"Brain"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","article-title":"Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers","volume":"80","author":"Mattsson-Carlgren","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat. Med."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-022-01925-w","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer's disease","volume":"28","author":"Mila-Aloma","year":"2022","journal-title":"Nat. Med."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/alz.12647","article-title":"Medical comorbidities and ethnicity impact plasma Alzheimer\u2019s disease biomarkers: Important considerations for clinical trials and practice","volume":"19","author":"O'Bryant","year":"2023","journal-title":"Alzheimers Dement."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jama.2024.13855","article-title":"Blood biomarkers to detect Alzheimer disease in primary care and secondary care","volume":"331","author":"Palmqvist","year":"2024","journal-title":"JAMA"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/alz.13542","article-title":"Plasma A\u03b242\/A\u03b240 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease","volume":"20","author":"Rissman","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1212\/WNL.0000000000200358","article-title":"Effect of Race on Prediction of Brain Amyloidosis by Plasma A\u03b242\/A\u03b240, Phosphorylated Tau, and Neurofilament Light","volume":"99","author":"Schindler","year":"2022","journal-title":"Neurology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e1823","DOI":"10.1212\/WNL.0000000000012775","article-title":"Predicting symptom onset in sporadic Alzheimer disease with amyloid PET","volume":"97","author":"Schindler","year":"2021","journal-title":"Neurology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1038\/s41598-025-34241-7","article-title":"Plasma p-tau217, quantified by the fully automated LUMIPULSE G platform, outperforms p-tau181 in predicting amyloid pathology in cognitive complaints patients","volume":"16","author":"Silva-Spinola","year":"2026","journal-title":"Sci. Rep."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e12921","DOI":"10.15252\/emmm.202012921","article-title":"Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum","volume":"12","author":"Su\u00e1rez-Calvet","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer's disease: towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e975","DOI":"10.1212\/WNL.0000000000011416","article-title":"Frequency of biologically defined Alzheimer disease in relation to age, sex, APOE \u03b54, and cognitive impairment","volume":"96","author":"Therriault","year":"2021","journal-title":"Neurology"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2021","journal-title":"Nat. Med."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e12204","DOI":"10.1002\/dad2.12204","article-title":"Development and validation of a high-sensitivity assay for measuring p217+tau in plasma","volume":"13","author":"Triana-Baltzer","year":"2021","journal-title":"Alzheimers Dement (Amst)."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"102507","DOI":"10.1016\/j.arr.2024.102507","article-title":"Neuroimaging and biofluid biomarkers across race and ethnicity in older adults across the spectrum of cognition","volume":"101","author":"Wang","year":"2024","journal-title":"Ageing Res. Rev."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1834591\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:44:55Z","timestamp":1780469095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1834591\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":34,"alternative-id":["10.3389\/fnagi.2026.1834591"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1834591","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1834591"}}